Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of empagliflozin and dapagliflozin in urinary tract infection risk among hyperglycemic women
IRCT20250129064554N1Phase 4Completed
- Sponsor
- Aja University of Medical Sciences
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of empagliflozin and dapagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Aja University of Medical Sciences. Primary endpoint: Incidence of urinary tract infection. Started Oct 2024; status: completed.
02
Drugs
empagliflozindapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20250129064554N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250129064554N1.